Last updated 2026-07-27
- Went public on NASDAQ (ORMP), Feb 2013
- Raised $100M Follow-on PO, Sep 2021
- Raised $75M Follow-on PO, Mar 2024
Total raised
$494.5M
Last: Public Offering 2021-11
Stage
Public
Founded
2006
Headcount
13
HQ
Jerusalem, Israel
Sector
Health Tech & Life Sciences
About
Oramed Pharmaceuticals Inc. is a publicly traded company focused on the research and development of oral drug delivery systems, primarily an oral insulin capsule for treating type 2 diabetes. The company's proprietary Protein Oral Delivery (POD™) technology is designed to protect therapeutic proteins from enzymatic breakdown in the gastrointestinal tract and enhance their absorption. Oramed is also developing an oral GLP-1 analog capsule and an oral leptin capsule. The company is transitioning its business model to include strategically operating medical technology businesses through acquiring controlling interests in a portfolio of entities.
Funding history · 28 rounds · $494.5M total
2026-07
Convertible Debt
$11.2M
2024-03
Follow-on PO
$75.0M
2021-11
Follow-on PO
$50.0M
2021-09
Follow-on PO
$100.0M
2021-06
Follow-on PO
$28.0M
2020-12
Follow-on PO
$40.0M
2020-02
Follow-on PO
$21.0M
2019-09
Follow-on PO
$15.0M
2018-07
Follow-on PO
$18.1M
2017-04
Follow-on PO
$25.0M
2015-10
Follow-on PO
$12.0M
2015-06
Follow-on PO
$5.4M
2015-04
Follow-on PO
$25.0M
2014-11
PIPE
$5.0M
2013-12
Follow-on PO
$15.8M
2013-10
Follow-on PO
$8.9M
2013-07
Follow-on PO
$4.6M
2013-05
Grant
Undisclosed
2013-02
Follow-on PO
$8.5M
2012-11
PIPE
$684K
2012-08
PIPE
$3.6M
2011-04
Follow-on PO
$3.4M
2010-12
PIPE
$2.0M
2010-09
Follow-on PO
$3.3M
2010-04
Follow-on PO
$5.3M
2008-07
PIPE
$5.0M
2007-06
PIPE
$1.8M
2006-02
Follow-on PO
$1.0M
Headcount over time
From 8 (2018-09) to 16 (2026-03) · +8 (+100%) · 27 points · source: Finder history + radar grounding
Q&A
- What is Oramed Pharmaceuticals' primary focus?
- Oramed Pharmaceuticals is a clinical-stage pharmaceutical company that develops oral drug delivery systems for treatments typically administered via injection. Their main product is an oral insulin capsule for type 2 diabetes.
- What is Oramed Pharmaceuticals' current public status?
- Oramed Pharmaceuticals is a public company, listed on NASDAQ since April 2006 and on TASE since July 2017.
- What is Oramed Pharmaceuticals' proprietary technology?
- Oramed Pharmaceuticals utilizes its proprietary Protein Oral Delivery (POD™) technology, designed to protect therapeutic proteins from enzymatic breakdown in the gastrointestinal tract and enhance their absorption.
- What was Oramed Pharmaceuticals' most recent funding round?
- Oramed Pharmaceuticals completed a Public Offering in March 2024, raising $75,000,000.
- What is the employee count for Oramed Pharmaceuticals?
- Oramed Pharmaceuticals has an employee count in the 11-50 range.
- What is Oramed Pharmaceuticals' strategy regarding medical technology businesses?
- Oramed Pharmaceuticals is transitioning its business model to include strategically operating medical technology businesses by acquiring controlling interests in a portfolio of entities.
- What was a significant financial event for Oramed Pharmaceuticals in July 2026?
- In July 2026, Oramed Pharmaceuticals secured $11,160,000 through a Convertible Debt round.
- What recent strategic partnership did Oramed Pharmaceuticals announce in January 2026?
- In January 2026, Oramed Pharmaceuticals and Lifeward announced a strategic transaction that will transfer Oramed's oral drug delivery platform (POD™ Technology) to Lifeward, positioning Oramed as a significant shareholder in the new diversified biomedical innovation company.
- What was a key development for Oramed Pharmaceuticals in June 2026?
- In June 2026, Oramed Pharmaceuticals announced its inclusion in the U.S. small cap Russell 2000 and Russell 3000 Indexes.
Team · 2
Miriam Kidron
Founder · Founder
Nadav Kidron
Founder · Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2BB2CB2B2CB2G
Highlights
1 PatentsVerified
Tags
oral-drugsmedical-technologiespharmaceuticalsbiotechnologydrug-deliverydiabetespharma-companies
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | oramed.com |
|---|---|
| linkedin.com/company/365036 | |
| X / Twitter | twitter.com/oramedpharma |
| facebook.com/oramed.pharmaceuticals | |
| YouTube | youtube.com/channel/UCbX6pFqc7itKkSnJjxKIdJg |
| Wikipedia | en.wikipedia.org/wiki/Oramed |
| Wikidata | wikidata.org/wiki/Q28760388 |
Identifiers & details
| Legal name | Oramed Pharmaceuticals Inc. |
|---|---|
| Founded | 2006 |
| Employees (exact) | 13 |
| Offices | New York |
| Market cap | $113.7M |
| Status reason | Public on NASDAQ on Apr, 2006; Public on TASE on Jul, 2017 |
| Wikidata QID | Q28760388 |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| IPO | 2013-02 | NASDAQ | ORMP | |
| Public Offering | 2020-02 | NASDAQ | ORMP | $21.0M |
| Registered Direct Offering | 2021-11 | NASDAQ | ORMP | $50.0M |
Radar intelligence
Patents
| EPO | 8 |
|---|
Web history (Wayback)
| Domain | oramed.com |
|---|
Wikidata
| QID | Q28760388 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 513976712 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2007-05-14 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | yes |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | ממילא 20 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-25 | עדכון הפרה |